O Keefe Stevens Advisory Inc. Makes New $282,000 Investment in Merck & Co., Inc. (NYSE:MRK)

O Keefe Stevens Advisory Inc. purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,651 shares of the company’s stock, valued at approximately $282,000.

A number of other large investors have also bought and sold shares of the stock. Sowa Financial Group Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $27,000. Total Clarity Wealth Management Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $27,000. Stephenson National Bank & Trust acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $28,000. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Merck & Co., Inc. by 180.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock valued at $32,000 after purchasing an additional 271 shares during the last quarter. Finally, Lion Street Advisors LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at $35,000. 74.33% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MRK traded down $1.02 during midday trading on Wednesday, hitting $77.70. The company had a trading volume of 4,152,740 shares, compared to its average volume of 10,337,286. The company’s 50 day moving average price is $78.23 and its 200 day moving average price is $81.49. The stock has a market cap of $198.57 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 2.22 and a beta of 0.48. Merck & Co., Inc. has a 52 week low of $65.25 and a 52 week high of $92.64. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, April 28th. The company reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.16. The company had revenue of $12.06 billion during the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.22 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 5.3 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 15th were given a $0.61 dividend. This represents a $2.44 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend was Friday, June 12th. Merck & Co., Inc.’s payout ratio is currently 47.01%.

In other news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $387,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.28% of the stock is currently owned by insiders.

Several research firms recently weighed in on MRK. Royal Bank of Canada reduced their target price on shares of Merck & Co., Inc. from $92.00 to $89.00 and set a “sector perform” rating on the stock in a report on Wednesday, April 1st. Credit Suisse Group restated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a report on Monday, May 4th. Mizuho restated a “buy” rating and set a $100.00 target price on shares of Merck & Co., Inc. in a report on Tuesday, June 23rd. Argus reduced their target price on shares of Merck & Co., Inc. from $105.00 to $95.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Finally, ValuEngine lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Monday, June 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $94.15.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Cost of Goods Sold (COGS)

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.